Trials / Completed
CompletedNCT00056836
A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration
A Phase III, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects With Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 720 (planned)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether injections of rhuFab V2 into the eye can prevent vision loss in patients with age-related macular degeneration, and also to evaluate the safety of this treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rhuFab V2 (ranibizumab) |
Timeline
- Start date
- 2003-03-01
- Completion
- 2005-12-01
- First posted
- 2003-03-26
- Last updated
- 2014-05-16
Source: ClinicalTrials.gov record NCT00056836. Inclusion in this directory is not an endorsement.